Clinical Pharmacology and Cardiovascular Safety of Naproxen

about

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.Synergism between Naproxen and Rutin in a Mouse Model of Visceral Pain.Cardiorenal Safety of OTC Analgesics.

P2860

Q41809872-E0776463-E5FA-41E1-8A41-99BD62FCC8C3 Q48238375-FA364453-29DE-46AE-BE26-1E2FCB442C30 Q49936659-B431E25B-0653-4899-82D1-18811A655518

P2860

Clinical Pharmacology and Cardiovascular Safety of Naproxen

Item

http://www.wikidata.org/entity/Q30360728

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@ast

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@en

type

Item

label

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@ast

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@en

prefLabel

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@ast

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@en

P1476

Clinical Pharmacology and Cardiovascular Safety of Naproxen

@en

P2093

Dominick J Angiolillo

http://www.w3.org/2001/XMLSchema#string

Steven M Weisman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

Acetaminophen for osteoarthritis

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

Cyclooxygenase inhibition and thrombogenicity

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs

P2888

s40256-016-0200-5

P304

97-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40256-016-0200-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018895482

http://www.w3.org/2001/XMLSchema#string

P698

27826802

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

mechanism of action

cardiovascular disease

polycyclic compound

hydrocarbon

P932

5340840

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacology and Cardiovascular Safety of Naproxen

about

P2860

P2860

Clinical Pharmacology and Cardiovascular Safety of Naproxen

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932